• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

340B 计划与《平价医疗法案》(ACA)保费的关联:2018 年至 2022 年的纵向分析

The Association of the 340B Program with Affordable Care Act (ACA) Premiums: A Longitudinal Analysis from 2018 to 2022.

作者信息

Masia Neal, Motyka James D, Westrich Kimberly, Campbell Jon D

机构信息

Health Capital Group, LLC and Columbia University, New York, NY, USA.

National Pharmaceutical Council, Washington, DC, USA.

出版信息

Inquiry. 2025 Jan-Dec;62:469580251370317. doi: 10.1177/00469580251370317. Epub 2025 Sep 4.

DOI:10.1177/00469580251370317
PMID:40905271
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12411698/
Abstract

We tested whether the 340B program impacts Affordable Care Act (ACA) premiums. Data from 2018 to 2022 was used to establish a baseline for silver benchmark premiums and other key measures, including: the number of active 340B sites per 10,000 people in a county (Hospital Site Density, or HSD), ACA benchmark plan premiums for every county, and measures likely to influence insurance premiums including per capita income, unemployment, and hospital market power. We used a multivariate fixed effects regression that included state and year effects, the explanatory variables, and the county-level HSD for each year. The impact of 340B on ACA premiums was illustrated using 2022 data. We estimate that a 1-unit change in 340B HSD was associated with a 1.1% (95% CI 0.73-1.15) change in the benchmark ACA premium. In 2022, the mean county 340B HSD was 1.63, and the mean Silver Benchmark Plan monthly premium was $500. After adjusting for per capita income, hospital concentration index, and other factors, the mean 340B HSD accounted for 1.8% (95% CI: 1.3-2.1) of the average Silver Benchmark Plan monthly premium, or $8.90 (95% CI $6.50-$10.25) per month, implying a cost in additional subsidies of over $106 per year per subsidized ACA enrollee. The results support that the 340B program is associated with a financially meaningful component of ACA premiums.

摘要

我们测试了340B计划是否会影响《平价医疗法案》(ACA)的保费。利用2018年至2022年的数据建立了银色基准保费及其他关键指标的基线,这些指标包括:每10000人中活跃的340B机构数量(医院机构密度,即HSD)、每个县的ACA基准计划保费,以及可能影响保险保费的指标,包括人均收入、失业率和医院市场势力。我们使用了一个多元固定效应回归模型,该模型包括州和年份效应、解释变量以及每年的县级HSD。利用2022年的数据说明了340B对ACA保费的影响。我们估计,340B HSD每变化1个单位,与基准ACA保费变化1.1%(95%置信区间0.73 - 1.15)相关。2022年,各县340B HSD的平均值为1.63,银色基准计划的月均保费为500美元。在调整了人均收入、医院集中度指数和其他因素后,340B HSD的平均值占银色基准计划月均保费的1.8%(95%置信区间:1.3 - 2.1),即每月8.90美元(95%置信区间6.50 - 10.25美元),这意味着每个获得补贴的ACA参保人每年额外补贴成本超过106美元。结果支持340B计划与ACA保费中具有财务意义的组成部分相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0669/12411698/f56162141ea5/10.1177_00469580251370317-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0669/12411698/f56162141ea5/10.1177_00469580251370317-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0669/12411698/f56162141ea5/10.1177_00469580251370317-fig1.jpg

相似文献

1
The Association of the 340B Program with Affordable Care Act (ACA) Premiums: A Longitudinal Analysis from 2018 to 2022.340B 计划与《平价医疗法案》(ACA)保费的关联:2018 年至 2022 年的纵向分析
Inquiry. 2025 Jan-Dec;62:469580251370317. doi: 10.1177/00469580251370317. Epub 2025 Sep 4.
2
Private Medicare plans' responses to benchmark changes and competition before and after the Affordable Care Act's payment cuts.《平价医疗法案》支付削减前后,私人医疗保险计划对基准变化及竞争的应对措施。
Health Serv Res. 2025 Apr;60(2):e14392. doi: 10.1111/1475-6773.14392. Epub 2024 Oct 21.
3
Who Enrolls in Coverage and Who Remains Uninsured? Medicaid Take-Up Before and After the Affordable Care Act and During Unwinding.哪些人参加了保险,哪些人仍未参保?《平价医疗法案》实施前后及医保覆盖范围缩减期间的医疗补助计划参保情况
Milbank Q. 2025 Jun;103(2):349-389. doi: 10.1111/1468-0009.70020. Epub 2025 May 26.
4
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
5
Health Care Utilization and Costs for Older Adults Aging Into Medicare After the Affordable Care Act.《平价医疗法案》实施后步入医疗保险体系的老年人的医疗保健利用情况及费用
JAMA Health Forum. 2025 Jan 3;6(1):e245025. doi: 10.1001/jamahealthforum.2024.5025.
6
Differences in Healthcare Utilization in Children with Developmental Disabilities Following Value-Based Care Coordination Policies.基于价值的医疗协同政策对发育障碍儿童医疗利用的影响差异。
J Healthc Manag. 2024;69(2):140-155. doi: 10.1097/JHM-D-23-00031.
7
Medicaid and CHIP Premiums and Access to Care: A Systematic Review.医疗补助与儿童健康保险计划的保费及医疗服务可及性:一项系统综述
Pediatrics. 2016 Mar;137(3):e20152440. doi: 10.1542/peds.2015-2440. Epub 2016 Feb 19.
8
Intensive case management for severe mental illness.严重精神疾病的强化个案管理。
Cochrane Database Syst Rev. 2017 Jan 6;1(1):CD007906. doi: 10.1002/14651858.CD007906.pub3.
9
Outcomes of the 340B Drug Pricing Program: A Scoping Review.340B 药品定价计划的结果:范围综述。
JAMA Health Forum. 2023 Nov 3;4(11):e233716. doi: 10.1001/jamahealthforum.2023.3716.
10
Key Provisions of the Patient Protection and Affordable Care Act (ACA): A Systematic Review and Presentation of Early Research Findings.《患者保护与平价医疗法案》(ACA)的关键条款:系统评价与早期研究结果展示
Health Serv Res. 2016 Oct;51(5):1735-71. doi: 10.1111/1475-6773.12511. Epub 2016 Jun 5.

本文引用的文献

1
Hospital Prices for Physician-Administered Drugs for Patients with Private Insurance.私立保险患者的医生管理药物的医院价格。
N Engl J Med. 2024 Jan 25;390(4):338-345. doi: 10.1056/NEJMsa2306609.
2
Outcomes of the 340B Drug Pricing Program: A Scoping Review.340B 药品定价计划的结果:范围综述。
JAMA Health Forum. 2023 Nov 3;4(11):e233716. doi: 10.1001/jamahealthforum.2023.3716.
3
Association Between New 340B Program Participation and Commercial Insurance Spending on Outpatient Biologic Oncology Drugs.新 340B 计划参与度与生物肿瘤学药物门诊商业保险支出的关联性。
JAMA Health Forum. 2023 Jun 2;4(6):e231485. doi: 10.1001/jamahealthforum.2023.1485.
4
Assessment of US Pharmacies Contracted With Health Care Institutions Under the 340B Drug Pricing Program by Neighborhood Socioeconomic Characteristics.评估参与 340B 药品定价计划的美国药店的邻里社会经济特征与医疗机构的合同情况。
JAMA Health Forum. 2022 Jun 17;3(6):e221435. doi: 10.1001/jamahealthforum.2022.1435. eCollection 2022 Jun.
5
Consequences of the 340B Drug Pricing Program.340B药品定价计划的后果。
N Engl J Med. 2018 May 24;378(21):2053-2054. doi: 10.1056/NEJMc1802999.
6
Impact of the 340B Drug Pricing Program on Cancer Care Site and Spending in Medicare.340B 药品定价计划对医疗保险中癌症护理地点和支出的影响。
Health Serv Res. 2018 Oct;53(5):3528-3548. doi: 10.1111/1475-6773.12823. Epub 2018 Jan 22.